About Synergen
Synergen is a Healthcare company based in Thousand Oaks (United States) founded in 1986, and was acquired by Vidaris in July 2018. Protein-based drugs for the treatment of inflammatory diseases. Its chief executive, as recorded, is Bryan Byrd. Its focus areas include Diversified Pharmaceuticals.
Company details
Synergen is a maker of protein-based drugs, especially for the treatment of inflammatory diseases. Was acquired by Amgen for 262M or 9.25 a share in December, 1994. The company was renamed as Amgen Boulder and operates as a wholly owned subsidiary of Amgen.
- Headquarters Thousand Oaks, United States
- Stage Acquired
- SectorsHealthcare
- Website synergen.com
- Social LinkedIn
- Acquired by Vidaris (Jul 2018)
Investors in Synergen
Synergen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Amgen and Vidaris.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Niche consulting services are provided for high-performance buildings and structures. | 1923 | vidaris.com | New York, United States |
Investor details for Synergen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Synergen
1 people are tracked at Synergen (1 in leadership).
| Name | Role | Group |
|---|---|---|
Bryan Byrd | CEO & President | Leadership |
Complete people profiles for Synergen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Synergen (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Synergen
Synergen was founded in 1986.
Synergen is headquartered in Thousand Oaks, United States. It is registered at Thousand Oaks, California, United States.
Bryan Byrd is the CEO of Synergen, as recorded in our data.
Synergen is a maker of protein-based drugs, especially for the treatment of inflammatory diseases. Was acquired by Amgen for 262M or 9.25 a share in December, 1994. The company was renamed as Amgen Boulder and operates as a wholly owned subsidiary of Amgen.
Yes. Synergen was acquired by Vidaris in July 2018.